2018
DOI: 10.1016/j.juro.2018.02.1286
|View full text |Cite
|
Sign up to set email alerts
|

Mp40-19 Initial Experience of Novel Hybrid Psma Pet / Mri Imaging for Lymph Node Staging in Prostate Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…12 It is hoped that through a multicentre prospective clinical trial, 68 Ga-PSMA-PET/CT can be directly compared with conventional scans to better understand if the method has improved diagnostic ability in primary staging, with subsequent positive effect on patient management. 13 In addition to PET/CT, current studies suggest that the PSMA PET/MRI offers even further advantages by identifying lymph-node metastases that would have been missed on CT. 14 This method of PSMA PET/MRI has been seen to be particularly useful when PSA levels are low, showing a high detection rate for locally recurrent disease. 15 In addition, PSMA has further theranostic applications in local salvage therapy, such as in the use of lutetium-177-labelled PSMA ( 177 Lu-PSMA), which directly treats prostate cancers with the added benefit of a reduction in side effects.…”
Section: Imaging and Diagnosticsmentioning
confidence: 99%
See 1 more Smart Citation
“…12 It is hoped that through a multicentre prospective clinical trial, 68 Ga-PSMA-PET/CT can be directly compared with conventional scans to better understand if the method has improved diagnostic ability in primary staging, with subsequent positive effect on patient management. 13 In addition to PET/CT, current studies suggest that the PSMA PET/MRI offers even further advantages by identifying lymph-node metastases that would have been missed on CT. 14 This method of PSMA PET/MRI has been seen to be particularly useful when PSA levels are low, showing a high detection rate for locally recurrent disease. 15 In addition, PSMA has further theranostic applications in local salvage therapy, such as in the use of lutetium-177-labelled PSMA ( 177 Lu-PSMA), which directly treats prostate cancers with the added benefit of a reduction in side effects.…”
Section: Imaging and Diagnosticsmentioning
confidence: 99%
“…In addition to PET/CT, current studies suggest that the PSMA PET/MRI offers even further advantages by identifying lymph-node metastases that would have been missed on CT. 14 This method of PSMA PET/MRI has been seen to be particularly useful when PSA levels are low, showing a high detection rate for locally recurrent disease. 15 In addition, PSMA has further theranostic applications in local salvage therapy, such as in the use of lutetium-177-labelled PSMA ( 177 Lu-PSMA), which directly treats prostate cancers with the added benefit of a reduction in side effects.…”
Section: Imaging and Diagnosticsmentioning
confidence: 99%